期刊
NANOMEDICINE
卷 12, 期 12, 页码 1475-1490出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2017-0069
关键词
cancer treatment; Doxil; HDM2 overexpressed tumors; PEGylated liposome doxorubicin; PNC27 peptide; targeting ligand
资金
- Nanotechnology Research Center, Mashhad University of Medical Sciences
- Biotechnology Research Center, Mashhad University of Medical Sciences
Aim: To investigate the potential of PNC27 peptide, 12-26 of p53 with high affinity for HDM2 protein, as targeting ligand for Doxil to improve its antitumor activity. Materials & methods: Doxil postinserted with 25, 50, 100 and 200 PNC27 peptides per liposome. Flow cytometry and confocal analysis were performed on C26 colon carcinoma (HDM2 positive) and B16F0 melanoma (HDM2 negative) cells. In vivo studies were performed on BALB/c mice bearing C26 and C57BL/6 mice bearing B16F0 tumor models. Results: PNC27-Doxil showed significant cellular uptake and cytotoxicity in C26 cells compared with Doxil. PNC27-Doxil (100 PNC27 peptide) significantly improved therapeutic efficacy of Doxil without compromising its biodistribution in C26 tumor. However, these results were not observed in B16F0 cells. Conclusion: PNC27 is a promising targeting ligand for Doxil against HDM2-positive cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据